Clinical Trial Update: Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416 [Phase 1]

View source ↗

Summary

Phase 1 evaluation of safety, tolerability, and pharmacokinetics for repeat oral doses of GSK580416; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infection

Drugs mentioned

• GSK580416

Snippet

Sponsor: GlaxoSmithKline | Conditions: Bacterial Infection, Infections, Bacterial | Phase 1 | Status: TERMINATED